Appleton Partners Inc. MA Has $9.25 Million Stake in Solventum Corporation $SOLV

Appleton Partners Inc. MA raised its position in shares of Solventum Corporation (NYSE:SOLV) by 60.2% during the first quarter, HoldingsChannel.com reports. The fund owned 141,689 shares of the company’s stock after buying an additional 53,243 shares during the quarter. Appleton Partners Inc. MA’s holdings in Solventum were worth $9,252,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Hilltop National Bank grew its holdings in Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after purchasing an additional 129 shares during the period. CrossGen Wealth LLC acquired a new position in shares of Solventum during the fourth quarter valued at about $25,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Solventum during the third quarter valued at about $25,000. JNBA Financial Advisors boosted its position in shares of Solventum by 205.4% during the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after purchasing an additional 228 shares in the last quarter. Finally, CYBER HORNET ETFs LLC bought a new position in shares of Solventum during the 2nd quarter worth about $28,000.

Solventum Trading Down 0.1%

SOLV opened at $78.22 on Monday. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. Solventum Corporation has a fifty-two week low of $62.38 and a fifty-two week high of $88.20. The firm has a market capitalization of $13.55 billion, a PE ratio of 9.59, a P/E/G ratio of 1.21 and a beta of 0.66. The company’s 50-day moving average is $75.43 and its 200 day moving average is $74.43.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the prior year, the company posted $1.34 earnings per share. Solventum’s revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, research analysts predict that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SOLV has been the subject of several research reports. BTIG Research restated a “buy” rating and issued a $89.00 target price on shares of Solventum in a research note on Wednesday, May 6th. Wedbush assumed coverage on Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 price target on the stock. UBS Group cut Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research note on Thursday, May 14th. KeyCorp boosted their price objective on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Finally, Wells Fargo & Company lowered their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 6th. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $83.73.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.